Key result
Targeted cancer therapies, including trastuzumab, bevacizumab, imatinib, and sunitinib, are associated with cardiovascular toxicities such as left ventricular dysfunction, heart failure, and hypertension.
Targeted cancer therapies such as trastuzumab, bevacizumab, sunitinib, and imatinib are associated with significant cardiovascular toxicities, necessitating awareness of their incidence and molecular mechanisms.
Answers are grounded in this paper and cite their sources.
Highlights the need for routine cardiovascular surveillance during targeted oncology regimens; leaves open the optimal cardioprotective strategies.
Compared with traditional chemotherapy, targeted cancer therapy is a novel strategy in which key molecules in signaling pathways involved in carcinogenesis and tumor spread are inhibited. Targeted cancer therapy has fewer adverse effects on normal cells and is considered to be the future of chemotherapy. However, targeted cancer therapy-induced cardiovascular toxicities are occasionally critical issues in patients who receive novel anticancer agents, such as trastuzumab, bevacizumab, sunitinib and imatinib. The aim of this review was to discuss these most commonly used drugs and associated incidence of cardiotoxicities, including left ventricular dysfunction, heart failure, hypertension and thromboembolic events, as well as summarize their respective molecular mechanisms of cardiovascular adverse effects.
No takes yet. Share an insight, caveat, or question.
CHEN et al. (2016) conducted a review in Cancer. Targeted cancer therapies (trastuzumab, bevacizumab, imatinib, sunitinib) was evaluated. Targeted cancer therapies, including trastuzumab, bevacizumab, imatinib, and sunitinib, are associated with cardiovascular toxicities such as left ventricular dysfunction, heart failure, and hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: